CpG Island Hypermethylation Profile in the Serum of Men With Clinically Localized and Hormone Refractory Metastatic Prostate Cancer
- 29 February 2008
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 179 (2), 529-535
- https://doi.org/10.1016/j.juro.2007.09.038
Abstract
Purpose: We have noted that hypermethylation at GSTP1 in the preoperative serum of men with localized prostate cancer predicts early prostate specific antigen failure following surgical treatment. In this study we investigated the hypermethylation profile of several genes in the serum of men with localized and hormone refractory prostate cancer. Materials and Methods: We assayed the serum of 192 men with clinically localized prostate cancer and 18 with hormone refractory metastatic disease. A total of 35 serum samples from patients with negative prostate biopsy served as a negative control. CpG Island hypermethylation status of certain genes was assessed, including MDR1, EDNRB, CD44, NEP, PTGS2, RASSF1A, RAR-β and ESR1. The results of hypermethylation at GSTP1 were included from a previous study. Results: CpG island hypermethylation at MDR1 was positive in 38.2% of cases without PSA recurrence and in 16.1% of those with biochemical recurrence after radical prostatectomy. DNA hypermethylation at the remaining 7 gene loci was not detected in the serum of patients with localized prostate cancer. In serum from metastatic prostate cancer cases CpG island hypermethylation was detected at MDR1 in 15 (83.3%), EDNRB in 9 (50%), RAR-β in 7 (38.9%), GTSP1 in 5 (27.8%) and NEP or RASSF1A in 3 (16.7%). CpG island hypermethylation at CD44, PTGS2 or ESR was not detected in any samples. All histologically normal cases were negative for CpG island hypermethylation. Conclusions: DNA hypermethylation at MDR1 was detected in cases of localized prostate cancer. CpG island hypermethylation at several gene loci was detected in men with advanced disease. No single gene was consistently observed to be hypermethylated in men with hormone refractory disease. These results suggest that the CpG island hypermethylation status of a defined panel of genes may be a useful biomarker in men with hormone refractory prostate cancer.Keywords
This publication has 20 references indexed in Scilit:
- LUMA (LUminometric Methylation Assay)—A high throughput method to the analysis of genomic DNA methylationExperimental Cell Research, 2006
- Association of Circulating Tumor Cells with Serum Tumor-Related Methylated DNA in Peripheral Blood of Melanoma PatientsCancer Research, 2006
- Combination of methylated-DNA precipitation and methylation-sensitive restriction enzymes (COMPARE-MS) for the rapid, sensitive and quantitative detection of DNA methylationNucleic Acids Research, 2006
- Predictive Utility of Circulating Methylated DNA in Serum of Melanoma Patients Receiving BiochemotherapyJournal of Clinical Oncology, 2005
- Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical ProstatectomyClinical Cancer Research, 2005
- Diagnostic and Prognostic Information in Prostate Cancer with the Help of a Small Set of Hypermethylated Gene LociClinical Cancer Research, 2005
- QuantitativeRARβ2HypermethylationClinical Cancer Research, 2004
- Hypermethylation of CpG Islands in Primary and Metastatic Human Prostate CancerCancer Research, 2004
- Heterogeneous gene methylation patterns among pre‐invasive and cancerous lesions of the prostate: A histopathologic study of whole mount prostate specimensThe Prostate, 2004
- Hypermethylation of GSTP1, CD44, and E‐cadherin genes in prostate cancer among US Blacks and WhitesThe Prostate, 2003